AU2001237875A1 - New self emulsifying drug delivery system - Google Patents
New self emulsifying drug delivery systemInfo
- Publication number
- AU2001237875A1 AU2001237875A1 AU2001237875A AU2001237875A AU2001237875A1 AU 2001237875 A1 AU2001237875 A1 AU 2001237875A1 AU 2001237875 A AU2001237875 A AU 2001237875A AU 2001237875 A AU2001237875 A AU 2001237875A AU 2001237875 A1 AU2001237875 A1 AU 2001237875A1
- Authority
- AU
- Australia
- Prior art keywords
- oil
- pharmaceutical composition
- surfactant
- pharmaceutical
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
NEW SELF EMULSIFYING DRUG DELIVERY SYSTEM
Field of the invention
The present invention is directed to a new pharmaceutical composition in form of an emulsion pre-concentrate. a unit dosage form comprising said composition, its use in therapy as well as a process for the preparation thereof.
Background and prior art
Non-steroidal anti-inflammatory drugs, commonly abbreviated NSAIDs, are well-known drugs for the treatment of pain and inflammation. One of the major drawbacks with NSAIDs is that they have severe gastro-intestinal side-effects. Patients undergoing treatment with NSAIDs for a longer period of time, such as naproxen, often experience problems with stomach gastrointestinal side-effects.
Nitrogen oxide releasing NSAID compounds (in the following NO-releasing NSAIDs), have recently been found to have an improved side-effect profile, see e.g. WO 94/04484, WO 94/12463, WO 95/09831 and WO 95/30641.
NO-releasing NSAIDs are lipophilic compounds with poor aqueous solubility. They can be classified into class 2 according to the Biopharmaceutical Classification System proposed by Amidon et al. (Pharm. Res. 12 (1995) pp. 413-420). Drugs of this class are characterised by low aqueous solubility but reasonably well permeability. A biopharmaceutical problem with these compounds is that their absorption from the gastrointestinal tract (GIT) may be dissolution rate limited, resulting in poor bioavailibility upon oral administration.
WO 95/08983 discloses a self-emulsifying composition for oral administration that forms a microemulsion in situ when in contact with biological fluids This composition can be characterised as a self-microemulsifying drug delivery system (SMEDDS), and comprises at least - an active compound. a lipophilic phase consisting of a mixture ot glyceπdes and fatty acid esters. a surface-active agent. a cosurfactant, and a hydrophilic phase which is achieved after ingestion by the physiological liquid of the digestive medium.
The present invention distinguishes in several aspects from WO 95/08983 and other SMEDDS Whereas the compositions disclosed in WO 95/08983 form a microemulsion in situ, the compositions of the present invention form an emulsion The SMEDDS of WO 95/08983 require the presence of a lipophilic phase to solubihse the active compound. Such a lipophilic solubiliser phase is not needed for the present invention since the active compound, the NO-releasing NSAID, is able to solely constitute the oil phase of the in situ emulsion. Compositions of WO 95/08983 comprise inter alia a cosurfactant in addition to a surface-active agent. The presence of a cosurfactant is not necessary for compositions of the present invention reducing toxicological concern to a minimum
EP 274 870 discloses a pharmaceutical composition comprising a non-steroidal anti- lnflammatory drug (NSAID) and a surfactant, the composition being capable of forming micelles containing the NSAID upon oral administration. These micelles have been found to present a particularly appropriate form to administer NSAIDs orally, alleviating their adverse effects on the gastrointestinal tract (GIT). Micelles are aggregates in which the surfactant molecules are generally arranged in a spheroidal structure with the hydrophobic region at the core shielded, in an aqueous solution, from the water by a mantle of outer hydrophilic regions. The drug is usually solubihsed in the surfactant. Micelles are to be contrasted in terms of their structure with emulsions which are formed by compositions of the present invention. Whereas micelles are thermodynamically stable one-phase-systems (according to the Gibbs phase law) in which the aggregates usually have a diameter of approximately two lengths of the surfactant molecule forming it, i.e. in the order of some
ten to hundred Angstrom (A) emulsions are much larger aggregates the order ot nanometers to micrometers in diameter, consisting ot an oilv core which is surrounded by one or several layers of surfactants Emulsions are generally two-phase-systems and they are thermodynamicallv unstable (but may be ineticallv stable) Another major difference between the compositions ot EP 274 870 and the present invention is the nature of the active compound Whereas NSAIDs are crystalline powders by nature, the NO-releasmg NSAIDs or mixtures of NO-releasing NSAIDs used in the present invention are in oil form or a thermosoftemng semisolid Moreover, micelles usually iequire a much higher drug surfactant ratio compared to the oil surfactant ratio required to form an emulsion
One of the unique features with NO-releasing NSAIDs is that many of these compounds are oils or thermosofte ng semisohds which are practically insoluble in water With high- dose NO-releasing NSAIDs, e g when the dose is above about 350 mg, it is difficult to formulate a tablet of reasonable size of the large amount of oil or semisolid The lipophilic NO-releasing NSAIDs can, however, be formulated as oil-in-water emulsions where the compound constitutes, or is part of, the oil phase emulsified in water by one or more surfactants
In pharmacokinetic animal studies it has been surprisingly found that such oil-in-water emulsions of NO-releasing NSAIDs display a much better bioavailability compared to the unemulsified substance A problem with emulsions is, however, that they are thermodynamically unstable and have a poor long-term storage stability since they often tend to coalescence, creaming/sedimentation or phase separation Moreover, they do not represent a convenient dosage form for oral administration since often large volumes are needed to incorporate one dose, and unpleasant bitter or soapy taste may be a major problem It is inter aha not possible to fill oil-in-water emulsions into gelatine capsules since the high water content of the emulsion is incompatible with the capsule shell and would dissolve it
Outline of the invention
The problems mentioned above have now been solved by providing a novel Self Emulsifying Drug Delivery System, commonly known as SEDDS, suitable for oral administration More particularly, the present invention is directed to a pharmaceutical composition suitable tor oral administration, in form of an emulsion pre-concentrate comprising
(I) a compound of the formula (I)
(u) one or more surfactants,
(m) optionally an oil or semi-solid fat,
said composition forming an in-situ oil-in-water emulsion upon contact with aqueous media such as gastrointestinal fluids
The composition according to the present invention may optionally further comprise one or more short-chain alcohols
The composition will form an in situ oil-in-water emulsion of small droplets of nanometer to micron size upon contact with gastrointestinal fluids, the droplets being constituted of a compound of the formula (I) above, forming the core of the droplet which is covered by one or several layers of surfactant The in situ formed oil-in-water emulsion will provide a good bioavailability of the compound of the formula (I) upon oral administration Storage stability of the emulsion is not a concern since the emulsion is not formed until the pre- concentrate has been taken by the patient, 1 e first at the moment of administration The possibly unpleasant taste of the pre-concentrate is not a problem when filled into capsules
The pharmaceutical composition according to the present invention is an emulsion pre-concentrate at the time of administration to a patient The emulsion pre-concentrate can be filled into single unit dosage forms such as capsules, drinking ampoules and dose cushions, or may alternatively be formed as other suitable dosage forms such as chewable soft pills and chewy-base lozenges
Upon contact with aqueous media such as gastrointestinal fluids, the emulsion pre- concentrate transforms into an oil-in-water emulsion Thus, the composition will form an in-situ oil-in-water emulsion in the gastrointestinal tract (GI tract) The drug release rate of the composition is determined by the droplet size of the in situ emulsion and the polarity ot the emulsion droplets, the latter being governed by the hydrophihc-lipophilic balance (HLB) of the drug/surfactant mixture, and the concentration of the surfactant Generally, small droplet size and high polarity gives rise to a high drug release rate (N H Shah et al Int J Pharm 106 (1994) pp 15-23)
The compound of the formula (I) above consists of naproxen, a butyl spacer and a NO-releasing moiety, said three parts being linked together into one single molecule Naproxen is by nature in form of a powder, whereas NO-releasing naproxen of the formula (I) above provides a compound in oil form as such at room temperature, due to the spacer This unique feature provides the advantage that no external lipophilic oil or semisolid matrix needs to be added to the emulsion pre-concentrate, since this is an inherent feature of the drug Additionally, a pharmacologically inert oil or semisolid fat may be added to the pharmaceutical composition by means of a filler or as a viscosity regulator A filling agent may be required to increase dosing accuracy for low doses A viscosity regulator may be required in order to adjust optimal viscosity for filling of the composition into e g capsules In particular high speed liquid filling of capsules requires careful adjustment of viscosity within a range that prevents splashing on the low viscosity end and thread formation on the high viscosity end Moreover, the \ iscosity range must be chosen so as to
give a pumpable formulation The viscosity range typically required for liquid filling of capsules is from 0 1 to 25 Pa s
The total amount of the compound of the formula (I) used in the composition of the s invention is preferably in the range 50- 1500 mg per unit dose In still a further preferred embodiment, the amount of the compound of the formula (I) used in the composition is
The wording "unit dose" is defined as the amount ot active compound administered in one lo single capsule, or dissolved in one glass of water
The wording "surfactant" is defined as surface-active amphiphihc compounds such as block co-polymers Preferred surfactants in accordance with the present invention are non-ionic surfactants, for example those containing polyethylene glycol (PEG) chains, la particularly block co-polymers such as poloxamers
Examples of suitable poloxamers are Poloxamer 407 (Pluronic F127 "), Poloxamer 401
(Pluromc L121®), Poloxamer 237 (Pluronic F87 ® ) Poloxamer 338 (Pluronic F138® ),
® ®
Poloxamer 331 (Pluronic L101 ), Poloxamer 231 (Pluronic L81 ), tetrafunctional 0 polyoxyethylene polyoxypropylene block copolymer of ethylene diamine, known as
Poloxamine 908 (Tetronic 908 ), Poloxamine 1307 (Tetronic 1307 " ), Poloxamine 1 107
® polyoxyethylene polyoxybutylene block copolymer, known as Polyglycol BM45 This list is only intended to serve as exemplification of surfactants that may be used in accordance with the present invention, and should not in any way be considered as 5 exhaustive or as limiting the invention
All surfactants described above are commercially available from e g BASF, Dow Chemicals, and Gattefosse
The total amount ot surtactant(s) in accordance with the invention may be within the range of from 12 5-6000 mg preferably of from 100-500 mg The ratio NO-releasing NSAID surfactant may vary from 1 0 1 to 1 10, preferably from 1 0 3 to 1 3
If an additional oil is added to the pharmaceutical composition this may be any oil as long as it is inert and compatible with the capsule material, as well as being acceptable for use in pharmaceuticals A person skilled in the art will appreciate which oil to select for the intended purpose Examples of suitable oils that may be used in accordance with the present invention are vegetable oils such as coconut oil, corn oil soybean oil rapeseed oil, safflower oil, and castor oil Also animαlic oils such as fish oil and tπglyceπdes are suitable for the purposes of the present invention
If a semi-solid fat is used as a filler for the pharmaceutical composition, this may preferably be selected from mono-, di- and tπglyceπdes, fatty acid alcohols such as stearyl
® ® ® alcohol, Gelucires 33/01 , 39/01 , 43/01 , glyceryl palmitostearate such as Precirol
® ATO5 Gelucire is a mixture obtained by mixing mono-, di-, and tπ-esters of glycerol, mono- and di-esters of PEG, or free PEG
If an oil or semi-solid fat is used in the pharmaceutical composition according to the invention, this may serve as a filler or as a viscosity regulator
The wording "short-chain alcohols" used in accordance with the present invention is herein defined as linear or branched mono-, di- or tπ-alcohols having 1-6 carbon atoms Examples of such short-chain alcohols useful in accordance with the invention are ethanol, propylene glycol and glycerol
If a short-chain alcohol is added to the pharmaceutical composition according to the invention, the solubility is enhanced and a smaller amount of surfactant is required
The pharmaceutical composition of the invention is filled into single dosage torms suitable for oral administration such as capsules, drinking ampoules and dose cushions or may be formulated as other suitable oral dosage forms such as chewable soft pills and chewy-base lozenges
In a preferred embodiment of the invention, the pharmaceutical composition is filled into hard gelatin capsules but capsules from alternative materials such as methylcellulose- based shells, and soft gelatine capsules may also be used
In an alternative embodiment of the invention, the pharmaceutical composition may be dissolved in e g a glass of water, thus allowing the pre-concentrate to form an emulsion which may be taken as an oral solution The compositions intended for dissolution prior to administration may be filled e g into sott gelatine capsules, plastic or aluminium cushions, or plastic or glass ampoules This feature is particularly advantageous for high dose compositions which would require a large capsule, for patients who have difficulty in swallowing capsules, and for pediatπc patients
In a preferred embodiment the pharmaceutical composition of the present invention is filled into capsules Preferred capsules are gelatin capsules which may be soft or hard The hard gelatine capsule consists of two pieces, a cap and a body, one fitting inside the other The hard gelatine capsules are produced empty and filled in a separate operation step The soft gelatin capsule is a capsule which is manufactured and filled in one single operation
As mentioned above, the emulsion pre-concentrate transforms into an oil-in-water emulsion upon contact with the gastrointestinal fluids, whereby the active drug is released Thus, the composition will form an in situ oil-in-water emulsion in the gastrointestinal tract (GI tract)
The pharmaceutical composition of the present invention is particularly useful in the treatment of pain and inflammation The wording "pain" is intended to include, but not
limited to, nociceptive and neuropathic pain or combinations thereof acute, intermittent and chronic pain, cancer pain, migraine and headaches of similar origin The wording "inflammation ' is intended to include, but not limited to, rheumatoid arthritis ostheoarthπtis. and juvenile arthritis
Methods of preparation
The pharmaceutical composition of the present invention may be prepared mainly by the following alternative methods
/. Mixing la) The oily compound of the formula (I) is put in a vessel, solid surfactant and sohd/oily fat (optional) is added The mixture is heated to the temperature corresponding to the melting point of the excipients , making the formulation fluid, mixed thoroughly until homogenous (visual inspection) and the pre-concentrate is filled into capsules suitable for oral administration
lb) Alternatively, the oily compound of the formula (I) is put in a vessel and fluid surfactant is added The mixture is mixed thoroughly until homogenous (visual inspection) and the pre-concentrate is filled into capsules suitable for oral administration
c) In a further alternative method, the oily compound of the formula (I) is put in a vessel, finely grinded (particle size < 177 um) solid surfactant is added The liquid mixture is mixed thoroughly until homogenous (visual inspection) and the pre-concentrate is filled into capsules suitable for oral administration
Id) In still an alternative method the semi-solid/sohd surfactant (s) is put in a vessel, and one or more alcohols are added The mixture is heated to the temperature corresponding to the melting point of the excipients, making the formulation fluid, mixed thoroughly until homogenous (visual inspection) The oily compound of the formula (I) is added, and the
mixture is mixed thoroughly until homogenous (visual inspection). The pre-concentrate is filled into capsules suitable for oral administration.
Ie) In yet a further alternative method the liquid surfactant(s) is put in a vessel, and one or more alcohols are added. The mixture is blended thoroughly until homogenous (visual inspection). The oily compound of the formula (I) is added, and the mixture is mixed thoroughly until homogenous (visual inspection). The pre-concentrate is filled into capsules suitable for oral administration
In order to fill a two-piece capsule or a softgel capsule with a liquid, the formulation must be within a certain viscosity range, as determined by the manufacturer, at the filling temperature suitable for the process. For a two-piece capsule the maximum filling temperature is roughly 70 °C. The viscosity of the formulation should normally be in the range 50-1000 cPoise (=0.05-1 Pas) at the temperature chosen for the filling process. For the filling of the formulation into softgel capsules, process temperature is not allowed to exceed 30-40 °C (the exact temperature depending on the manufacturer). The formulation must be liquid and have a viscosity that allows it to be pumpable at the filling temperature. In order to make the formulation liquid with an acceptable viscosity, several
® additives may be used, for example Cremophor EL .
//. Filling
For the filling procedure it is required that the composition is in liquid form at the temperature of filling. Semisolid thermosoftening compositions are therefore filled above the liqueifying temperature. Soft gelatine capsules are manufactured and filled in one operation, and may be filled at temperatures of up to 40 °C, whereas hard gelatine capsules may be filled at temperatures of up to 70 °C. Hard gelatin capsules filled with compositions that remain liquid at storage temperature require sealing, e.g. by gelatin banding, to prevent leakage. The process of liquid filling of hard gelatin capsules and product requirements are e.g. described in W.J. Bowtle, Pharmaceutical Technology Europe, October 1998; V.M. Young, Pharmaceutical Manufacturing and Packaging
Sourcer March 1999 and E T Coole Pharmaceutical Technology International September/ Octohei 1989 Using two piece capsules permits filling of more than one phase into a single capsule which may be desired for bi-or multiphase drug release (W J Bow tie et al Int J Pharm 141 (1996) pp 9-16) Several phases ot solidifying material can be filled in single steps The final phase may be liquid if required The number of phases is only restricted by the capsule size, and volume ot the single phases This special feature may also allow controlled release or separation of different drug substances formulated in the same capsule Additionally, capsules may be processed further e g by enteric coating
III. Characterisation of the formulations
In order to characterise formulations, the time required tor the formulation to form an oil- m-water emulsion upon contact with simulated gastric fluid, SGF, (without enzymes), is determined, and the formed emulsion is characterised SGF comprises of 7 millihtres concentrated hydrochloric acid, 2 grams of sodium chloride and distilled water to give the solution a total volume of 1 L The "emulsion forming test" is performed in test tubes (beaker) with magnetic stirring The test tube, containing a small magnet, is filled with 12 5 ml SGF without enzymes, corresponding to one tenth of the average volume of gastric fluid in humans, and formulation corresponding to one tenth of the dose of the active compound of formula (I) is added
The time for emulsion formation will vary from 30 seconds and up to 15 minutes, depending on the composition of the formulation If one or more short-chain alcohols are added, the time for emulsion formation will vary between 2-3 seconds and 3-4 minutes Also the average particle size of the formed emulsion is studied with Laser Diffraction, LD, or Photon Correlation Spectroscopy, PCS Depending on particle size either of the two methods may be used
Detailed description of the invention
The invention will now be described in more detail by the following examples which are not to be construed as limiting the invention
The following emulsion pre-concentrates were prepared
Example 1 amount f l (l) Compound of formula (I) 1000
(11) Pluronic F127® 1000
® A semi-solid formulation was obtained by melting 1 kg of Pluronic F127 ( Poloxamer
407) by heating to 62 °C The melt was stirred thoroughly to ensure that no solid particles were present 1 kg of the compound of formula (I) was added to the melted Pluronic
F127 ® , and the mixture was allowed to reach a temperature of 62 0 C The liquid formulation was mixed until homogenous (checked by visual inspection) The resulting liquid formulation was then filled into hard gelatin capsules The formulation becomes a semi-solid upon cooling (in the capsule)
Characterization
150 milligram of the formulation was put in 12 5 millilitres of SGF (without enzymes) and magnetic stirring The following results were obtained
Time to emulsion 13 minutes
Average particle size 2-3 μm
The viscosity was measured in a Stress Tech cone and plate viscometer, measurement system C 40 4 PC, at the shear rate 20 s The flow was more or less Newtonian
Example 2 amount [gl
(I) Compound of formula (I) 1000 (n) Pluronic L12 I R 1000
A liquid formulation was prepared by mixing 1 kg of the liquid surfactant Poloxamer 401, with 1 kg of the compound of formula (I) at room temperature The liquid formulation was mixed until homogenous (checked by visual inspection) The resulting liquid formulation was then filled into hard gelatin capsules
Characterization
150 milligram of the formulation was put in 12 5 millilitres of SGF (without enzymes) and magnetic stirring The following results were obtained
Time to emulsion 20 seconds Average particle size 1 1 μm
Example 3 amount fgl
(l) Compound of formula (I) 1000
® (n) Polyglycol BM 45 1000
(in) Sodium dodecyl sulphate 40
® A formulation was obtained by mixing 1 kg of Polyglycol BM 45 (Poloxamine 1 107), 40 grams of sodium dodecyl sulphate, acting as a co-surfactant, and 1 kg of the compound of formula (I) The liquid formulation was mixed until homogenous (checked by visual inspection) The resulting liquid formulation was then filled into hard gelatin capsules
Characterization
150 milligram of the formulation was put in 12 5 millilitres of SGF (without enzymes) and magnetic stirring The following results were obtained
Time to emulsion 15 minutes
Average particle size 0 7 μm
Example 4 amount fgl
(0 Compound of formula (I) 1000 (n) Pluronic F 127 500
®
(in) Cremophor EL 500
To be able to fill the semi-sohd formulation into soft gelatin capsules, process temperatures must be below 30-40 °C (the specific temperature depends on manufacturer) This means that the formulation must be fluid and pumpable below 30-40 °C To obtain a formulation
® fluid at this temperature, some of the surfactant was replaced with Cremophor EL A melt was prepared as described in Example 1 , except for the substitution of 0 5 kg
® surfactant with the same amount of Cremophor EL
Characterization
150 milligram of the formulation was put in 12 5 millilitres of SGF (without enzymes) and magnetic stirring The following results were obtained
Time to emulsion 9 minutes Average particle size 4-5 μm
Example 5 amount [g]
(I) Compound of formula (I) 1250
(ii) Pluronic F 127® 1500
(iii) Fractionated coconut oil 1880
To ensure that low dose formulations will have a good filling precision, and to fill a capsule of a certain volume to minimise the amount of air present, the active compound may be filled up to volume with aliquot part coconut oil. A semi-solid formulation was obtained by melting 1.500 kg of Pluronic F 127 ® (Poloxamer 407) by heating to 62 C. The melt was stirred thoroughly to ensure that no solid particles were present. 1.250 kg of the compound of formula (I) and 1.880 kg of fractionated coconut oil were added to the melted
® Pluronic F127 , and the mixture was allowed to reach a temperature of 62 C. The liquid formulation was mixed until homogenous (checked by visual inspection). The resulting liquid formulation was then filled into hard gelatin capsules.
Characterization
One tenth of the formulation was put in 12.5 millilitres of SGF (without enzymes) and magnetic stirring. The following results were obtained:
Time to form emulsion: 10 minutes
Average particle size: 5 μm
Example 6 amount [gl (i) Compound of formula (I) 62.5
(ii) Poloxamer 407 375
(iii) Fractionated coconut oil 312.5
The formulation was prepared as described for Example 5 above.
Characterization
Characterization was performed as for Example 5 above. The following results were obtained:
Time to form emulsion: 10 minutes Average particle size: 36 μm
Example 7 amount [gl
(i) Compound of formula (I) 62.5
® (ii) Poloxamer 407 375 (iii) Fractionated castor oil 312.5
The formulation was prepared as described for Examples 5 above.
Characterization Characterization was performed as for Example 5 above. The following results were obtained:
Time to form emulsion: 10 minutes
Average particle size: 81 μm
Example 8 amount Tgl
(i) Compound of formula (I) 3
(ii) Pluronic LI 27® 0.843
(iii) sorbitanmonolaurat 0.282
(iv) glycerol 0.375
® A semi-solid formulation was obtained by melting 0 843 gram of Pluronic F127
(Poloxamer 407), 0 282 gram ot sorbitanmonolaurat and 0 375 gram of glycerol by heating to 62 °C The melt was stirred thoroughly to ensure that no solid particles were present 3
Grams of the compound of formula (I) was added to the mixture The mixture was allowed to reach a temperature of 62 °C The liquid formulation was mixed until homogenous
(checked by visual inspection) The resulting liquid formulation was allowed to cool to a temperature of 30 °C, and was then filled into soft gelatin capsules The formulation becomes a semi-solid upon cooling (in the capsule)
Characterization
1 12 milligram of the formulation was put in 12 5 millilitres of SGF (without enzymes) and magnetic stirring The following result was obtained
Time to emulsion 2 5-3 5 minutes
Example 9 amount gl
(l) Compound of formula (I) 3
(n) Pluronic LI 27® 0 843
(in) sorbitanmonolaurat 0 282
(ιv) propylene glycol 0 375
® A semi-sohd formulation was obtained by melting 0 843 gram of Pluronic F127 (Poloxamer 407), 0 282 gram of sorbitanmonolaurat and 0 375 gram of propylene glycol by heating to 62 °C The melt was stirred thoroughly to ensure that no solid particles were present 3 Grams of the compound of formula (I) was added to the mixture The mixture was allowed to reach a temperature of 62 °C The liquid formulation was mixed until homogenous (checked by visual inspection) The resulting liquid formulation was allowed
to cool to a temperature of 30 °C, and was then filled into soft gelatin capsules The formulation stays liquid upon cooling (in the capsule)
Characterization
112 milligram of the formulation was put in 12 5 millilitres ot SGF (without enzymes) and magnetic stirring The following result was obtained
Time to emulsion within 20 seconds
Example 10 amount [gl
(l) Compound of formula (I) 3 (ii) Pluronic L101 " 0 506 (in) sorbitanmonolaurat 0 169 (IV) ethanol 0 225
A liquid formulation was prepared A solution of 0 506 gram of Pluronic L101 (Poloxamer 331), 0 169 gram of sorbitanmonolaurat and 0 225 gram of ethanol, was mixed until homogenous (checked by visual inspection) 3 Grams of the compound of formula (I) was added to the mixture, at room temperature The resulting liquid formulation was then filled into soft gelatin capsules
Characterization 97 milligram of the formulation was put in 12 5 millilitres of SGF (without enzymes) and magnetic stirring The following result was obtained
Time to emulsion within 20 seconds
In vivo study of formulations in mini pigs
A bioavailability study of formulations according to the present invention was performed after oral administration in fastened minipigs
6 male Gottingen SPF minipigs were used in the study At the start of the acclimatization period, the animals were 4 months old and had a weight of from 7 7 to 10 1 kg The animals were fasted for 12 hours before treatment and until the blood sample at 4 hours post treatment had been taken A supply of autoclaved hay was given daily as well Twice daily, the animals were offered domestic quality drinking water
A pharmaceutical composition of the invention, filled in a suitable unit dosage form according to the invention, was administered to each animal The dose levels were approximately 15 μmol/kg body weight 10 ml of tap water was given to facilitate the swallowing of the capsule or corresponding unit dosage
All visible signs of ill health and any behavioural changes were recorded daily Any deviation from normal was recorded with respect to time ot onset, duration and severity Included in the daily health check were observations of the consistency of faeces All animals were weighed on arrival and of the first day of of each treatment
Blood samples (5 ml) were taken from the jugular vein into Vacutainer tubes containing hepaπn Blood samples were taken before treatment (0) and at 15, 30 and 45 minutes. 1, 1 5, 2, 4, 7 and 24 hours after treatment
Claims (25)
1 A pharmaceutical composition suitable for oral administration, in form of an emulsion pre-concentrate, comprising
(l) a compound of the formula (I)
(II) one or more surfactants,
(III) optionally an oil or semi-sohd fat,
said composition forming an in-situ oil-in-water emulsion upon contact with aqueous media such as gastrointestinal fluids
2 A pharmaceutical composition according to claim 1 , further compπsing one or more short-chain alcohols
3 A pharmaceutical compositon according to claim 1 or 2, wherein the amount of the compound of formula (I) is from 50- 1500 mg per unit dose
4 A pharmaceutical compositon according to claim 3, wherein the amount of the compound of formula (I) is 125-500 mg per unit dose
5 A pharmaceutical compositon according to any one of the preceding claims, wherein the surfactant is a block co-polymer
6 A pharmaceutical compositon according to any one of the preceding claims, wherein the surfactant is a non-ionic surfactant
7 A pharmaceutical composition according to claim 6 v\ herein the non-ionic surfactant is a poloxamer
8 A pharmaceutical compositon according to claim 7 wherein the surfactant is selected from any one of Poloxamer 407, Poloxamer 401 , Poloxamer 237, Poloxamer 338, Poloxamer 331 , Poloxamer 231 , Poloxamine 908 Poloxamine 1307 Poloxamine 1 107 and polyoxyethylene polyoxybutylene block copolymer
9 A pharmaceutical compositon according to any one of the preceding claims, wherein the total amount of surfactant(s) is from 12 5-6000 mg
10 A pharmaceutical compositon according to claim 9, wherein the total amount of surfactant(s) is from 100-500 mg
11 A pharmaceutical compositon according to any one of the preceding claims, wherein the ratio of compound ot formula (I) surfactant is within the range of from 1 0 1 - 1 10
12 A pharmaceutical compositon according to claim 1 1 wherein the ratio ratio of compound of formula (I) surfactant is within the range of from 1 0 3 -1 3
13 A pharmaceutical compositon according to any one of the preceding claims, wherein an oil is present
14 A pharmaceutical compositon according to claim 13, wherein the oil is a vegetable oil
15 A pharmaceutical compositon according to claim 14. wherein the vegetable oil is selected from coconut oil, corn oil, soybean oil, rape seed oil, safflower oil and castor oil 1
16. A pharmaceutical composition according to claim 13. wherein the oil is an animalic oil.
17. A pharmaceutical composition according to claim 16. wherein the animalic oil is a fish oil or one or more mono-, di- or triglycerides.
18. A pharmaceutical composition according to any one of the preceding claims, wherein a semi-solid fat is used as filler.
19. A pharmaceutical composition according to claim 18, wherein the semi-solid fat is selected from mono-, di- and triglycerides.
20. A pharmaceutical composition according to claim 19, wherein the mono-, di- and triglycerides are selected from glyceryl palmitostearate, or a mixture of mono-, di and tri- esters of glycerol, mono- and di-esters of polyethylene glycol or free polyethylene glycol.
21. A pharmaceutical composition according to any one of claims 2-20. wherein the short- chain alcohol is selected from ethanol, propylene glycol and glycerol.
22. A pharmaceutical composition according to any one of the preceding claims, further comprising a co-surfactant.
23. A unit dosage form filled with a pharmaceutical composition according to any one of the preceding claims.
24. A unit dosage form according to claim 23, selected from any one of capsules, drinking ampoules, dose cushion, chewable soft pill, and chewy-base lozenges.
25. A unit dosage form according to claim 24, in form of a capsule. 26 A unit dosage form according to claim 25 wherein said capsule is a hard gelatine capsule
27 A unit dosage form according to claim 25, wherein said capsule is a soft gelatine capsule
28 An oral solution comprising a pharmaceutical composition according any one ot claims 1-22 dissolved in water
29 A method for the treatment of pain, whereby a pharmaceutical composition according to any one of the preceding claims, is administered to a patient in need of such treatment
30 A method for the treatment ot inflammation, whereby α pharmaceutical composition according to any one of the preceding claims, is administered to a patient in need of such treatment
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0000774-0 | 2000-03-08 | ||
| SE0000774A SE0000774D0 (en) | 2000-03-08 | 2000-03-08 | New formulation |
| PCT/SE2001/000466 WO2001066087A1 (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001237875A1 true AU2001237875A1 (en) | 2001-11-29 |
| AU2001237875B2 AU2001237875B2 (en) | 2005-05-12 |
Family
ID=20278740
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001237875A Ceased AU2001237875B2 (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
| AU3787501A Pending AU3787501A (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU3787501A Pending AU3787501A (en) | 2000-03-08 | 2001-03-06 | New self emulsifying drug delivery system |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US7736666B2 (en) |
| EP (1) | EP1267831B1 (en) |
| JP (1) | JP4656479B2 (en) |
| KR (1) | KR100771318B1 (en) |
| CN (1) | CN1283229C (en) |
| AR (1) | AR027554A1 (en) |
| AT (1) | ATE311173T1 (en) |
| AU (2) | AU2001237875B2 (en) |
| BR (1) | BR0109012B1 (en) |
| CA (1) | CA2401857A1 (en) |
| CZ (1) | CZ303524B6 (en) |
| DE (1) | DE60115402T2 (en) |
| DK (1) | DK1267831T3 (en) |
| EE (1) | EE200200483A (en) |
| ES (1) | ES2253354T3 (en) |
| HK (1) | HK1053795A1 (en) |
| HU (1) | HU229103B1 (en) |
| IL (1) | IL151380A0 (en) |
| IS (1) | IS6538A (en) |
| MX (1) | MXPA02008658A (en) |
| MY (1) | MY137749A (en) |
| NO (1) | NO331921B1 (en) |
| RU (1) | RU2275908C2 (en) |
| SE (1) | SE0000774D0 (en) |
| SI (1) | SI1267831T1 (en) |
| SK (1) | SK285749B6 (en) |
| UA (1) | UA76098C2 (en) |
| WO (1) | WO2001066087A1 (en) |
| ZA (1) | ZA200207109B (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9600070D0 (en) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| SE0000773D0 (en) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| IT1319202B1 (en) | 2000-10-12 | 2003-09-26 | Nicox Sa | DRUGS FOR INFLAMMATORY-BASED DISEASES. |
| SE0102993D0 (en) * | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
| ITMI20021392A1 (en) * | 2002-06-25 | 2003-12-29 | Nicox Sa | PHARMACEUTICAL FORMS FOR THE ORAL ADMINISTRATION OF LIQUID DRUGS AT AMBIENT TEMPERATURE EQUIPPED WITH BETTER BIOAVAILABILITY |
| US8802116B2 (en) | 2003-02-27 | 2014-08-12 | Novasel Australia Pty. Ltd. | Poloxamer emulsion preparations |
| AU2003900887A0 (en) * | 2003-02-27 | 2003-03-13 | Novasel Australia Pty Ltd | Poloxamer emulsion preparations |
| DE10353937A1 (en) * | 2003-11-18 | 2005-06-30 | Fresenius Medical Care Deutschland Gmbh | Device for transferring a reference liquid into a measuring device, measuring device with such a device and method for transmitting a reference fluid into a measuring device |
| GB0402679D0 (en) * | 2004-02-06 | 2004-03-10 | Novartis Ag | Organic compounds |
| NZ550894A (en) * | 2004-05-06 | 2011-02-25 | Emisphere Tech Inc | Solid dosage form of wetted heparin |
| ES2393324T3 (en) | 2004-05-14 | 2012-12-20 | Emisphere Technologies, Inc. | Compounds and compositions for administering active ingredients |
| KR100654617B1 (en) * | 2004-09-23 | 2006-12-08 | 정해현 | the pack of coffee mix and the box of coffee mix with stick |
| DK1906938T3 (en) * | 2005-07-26 | 2011-02-07 | Nicox Sa | Pharmaceutical formulation of nitric oxide derivatives of NSAIDs |
| EP2268160B1 (en) | 2008-03-20 | 2012-12-05 | Virun, Inc. | Emulsions including a peg-derivative of tocopherol |
| CA2715018C (en) | 2008-03-20 | 2012-11-13 | Virun, Inc. | Vitamin e derivatives and their uses |
| ES2661812T3 (en) | 2009-10-16 | 2018-04-04 | Mochida Pharmaceutical Co., Ltd. | Compositions |
| WO2011162802A1 (en) | 2010-06-21 | 2011-12-29 | Virun, Inc. | Compositions containing non-polar compounds |
| US9968557B1 (en) | 2011-02-09 | 2018-05-15 | Florida A&M University | Method of preparing modified multilayered microstructures with enhanced oral bioavailability |
| KR20240076240A (en) * | 2022-11-23 | 2024-05-30 | (주) 바이오인프라생명과학 | Method for manufacturing ultrasound-sensitive drug delivery carriers with double emulsion |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (en) | 1978-04-14 | 1979-10-15 | Haessle Ab | Gastric acid secretion |
| GB2105193B (en) | 1981-09-04 | 1984-09-12 | Glaxo Group Ltd | Pharmaceutical compositions containing non-steroidal anti-inflammatory agents |
| JPS59227870A (en) | 1983-06-07 | 1984-12-21 | Yamanouchi Pharmaceut Co Ltd | Novel 2-guanidinothiazoline derivative and its preparation |
| US4554276A (en) | 1983-10-03 | 1985-11-19 | Pfizer Inc. | 2-Amino-5-hydroxy-4-methylpyrimidine derivatives |
| US4522826A (en) | 1984-02-08 | 1985-06-11 | Richardson-Vicks Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
| US4552899A (en) | 1984-04-09 | 1985-11-12 | Analgesic Associates | Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (en) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | Pyridine derivative and preparation thereof |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| US4766117A (en) | 1984-10-11 | 1988-08-23 | Pfizer Inc. | Antiinflammatory compositions and methods |
| US4704278A (en) | 1984-10-17 | 1987-11-03 | American Home Products Corp (Del) | Fluidized magaldrate suspension |
| US4676984A (en) | 1985-08-14 | 1987-06-30 | American Home Products Corp. | Rehydratable antacid composition |
| US4965065A (en) | 1986-04-29 | 1990-10-23 | Bristol-Myers Squibb Company | Gastroprotective process and compositions |
| US4757060A (en) | 1986-03-04 | 1988-07-12 | Bristol-Myers Company | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers |
| US5037815A (en) | 1986-03-04 | 1991-08-06 | Bristol-Myers Squibb Co. | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers |
| US5043358A (en) | 1986-03-04 | 1991-08-27 | Bristol-Myers Squibb Company | Gastroprotective process |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US5260333A (en) | 1986-08-08 | 1993-11-09 | Bristol Myers Squibb Company | Effect of a combination of a terbutaline, diphenhydramine and ranitidine composition on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions |
| GB8630273D0 (en) | 1986-12-18 | 1987-01-28 | Til Medical Ltd | Pharmaceutical delivery systems |
| EP0320550A1 (en) | 1987-12-18 | 1989-06-21 | Bristol-Myers Company | Non steroidal anti-inflammatory drug composition containing H1 blockers, H2 blockers, beta adrenergic agonists or combinations thereof and an alkalizing agent |
| SE8804629D0 (en) | 1988-12-22 | 1988-12-22 | Ab Haessle | NEW THERAPEUTICALLY ACTIVE COMPOUNDS |
| NZ235877A (en) | 1989-11-02 | 1992-09-25 | Mcneil Ppc Inc | Composition comprising acetaminophen or nsaid and an h 1 or h 2 receptor blocker and/or proton pump inhibitor for treating overindulgence |
| US5204118A (en) | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| AU1252692A (en) | 1991-03-04 | 1992-10-06 | Warner-Lambert Company | Novel salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms |
| DE4131678A1 (en) | 1991-04-13 | 1992-10-15 | Beiersdorf Ag | STABLE MULTIPLE EMULSIONS |
| ES2130152T3 (en) | 1991-12-06 | 1999-07-01 | Glaxo Group Ltd | MEDICINES TO TREAT INFLAMMATORY PAIN OR ANALGESIA CONTAINING A NSAID AND RANITIDINE / BISMUTE CITRATE. |
| WO1993012817A1 (en) | 1991-12-20 | 1993-07-08 | Warner-Lambert Company | Therapeutic combinations useful in the treatment of gastroesophageal reflux disease |
| US5294433A (en) | 1992-04-15 | 1994-03-15 | The Procter & Gamble Company | Use of H-2 antagonists for treatment of gingivitis |
| IT1256345B (en) | 1992-08-20 | 1995-12-01 | NITRIC ESTERS OF PHENYLACETIC 2- (2,6-DI-HALO-PHENYLAMIN) DERIVATIVES AND PROCEDURE FOR THEIR PREPARATION | |
| CA2144155A1 (en) | 1992-09-29 | 1994-04-14 | Robert T. Sims | Ibuprofen-h2 antagonist combinations |
| IT1256450B (en) | 1992-11-26 | 1995-12-05 | Soldato Piero Del | NITRIC ESTERS WITH PHARMACOLOGICAL ACTIVITY AND PROCEDURE FOR THEIR PREPARATION |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| CH686761A5 (en) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Pharmaceutical formulations. |
| SE9301830D0 (en) | 1993-05-28 | 1993-05-28 | Ab Astra | NEW COMPOUNDS |
| DK66493D0 (en) | 1993-06-08 | 1993-06-08 | Ferring A S | PREPARATIONS FOR USE IN TREATMENT OF INFLAMMATORY GAS DISORDERS OR TO IMPROVE IMPROVED HEALTH |
| SE9302396D0 (en) | 1993-07-09 | 1993-07-09 | Ab Astra | A NOVEL COMPOUND FORM |
| US6054136A (en) | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| US6312704B1 (en) * | 1993-09-30 | 2001-11-06 | Gattefosse, S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| FR2710535B1 (en) * | 1993-09-30 | 1995-11-24 | Gattefosse Ets Sa | Composition for pharmaceutical or cosmetic use capable of forming a microemulsion. |
| US5700947A (en) * | 1993-10-06 | 1997-12-23 | Nicox S.A. | Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation |
| EP0724441A1 (en) | 1993-10-19 | 1996-08-07 | The Procter & Gamble Company | Picosulphate dosage form |
| US5514663A (en) | 1993-10-19 | 1996-05-07 | The Procter & Gamble Company | Senna dosage form |
| US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| US5643960A (en) | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
| CA2190087C (en) | 1994-05-10 | 2005-08-02 | Piero Del Soldato | Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic activities |
| EP1078628B1 (en) | 1994-07-08 | 2008-11-19 | AstraZeneca AB | Multiple unit tableted dosage form |
| SE9500478D0 (en) | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
| US5965160A (en) * | 1995-04-24 | 1999-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Self-emulsifiable formulation producing an oil-in-water emulsion |
| US5955451A (en) | 1995-05-12 | 1999-09-21 | The University Of Texas System Board Of Regents | Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein |
| EP0760237A1 (en) | 1995-08-30 | 1997-03-05 | Cipla Limited | Oil-in-water microemulsions |
| SE9600070D0 (en) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| US6231888B1 (en) | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
| WO1998022117A1 (en) | 1996-11-22 | 1998-05-28 | The Procter & Gamble Company | Compositions for the treatment of gastrointestinal disorders containing bismuth, and nsaid and one or more antimicrobials |
| SE510666C2 (en) | 1996-12-20 | 1999-06-14 | Astra Ab | New Crystal Modifications |
| US6160020A (en) | 1996-12-20 | 2000-12-12 | Mcneill-Ppc, Inc. | Alkali metal and alkaline-earth metal salts of acetaminophen |
| SE510643C2 (en) | 1997-06-27 | 1999-06-14 | Astra Ab | Thermodynamically stable omeprazole sodium form B |
| BR9810729B1 (en) * | 1997-07-29 | 2010-07-13 | pharmaceutical composition for acid lipophilic compounds arranged as a self-emulsifying formulation. | |
| EA002806B1 (en) | 1997-09-11 | 2002-10-31 | Нюкомед Данмарк А/С | Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaid) |
| US6395298B1 (en) | 1997-10-31 | 2002-05-28 | Pharmacia Corporation | Gellan gum tablet coating |
| JP2002501896A (en) | 1998-01-30 | 2002-01-22 | セプラコール， インク． | S-lansoprazole compositions and methods |
| CA2320963A1 (en) | 1998-01-30 | 1999-08-05 | Sepracor, Inc. | R-lansoprazole compositions and methods |
| WO1999056727A2 (en) | 1998-05-07 | 1999-11-11 | Elan Corporation, Plc | Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems |
| EP0984012A3 (en) | 1998-08-31 | 2001-01-10 | Pfizer Products Inc. | Nitric oxide releasing oxindole prodrugs with analgesic and anti-inflammatory properties |
| WO2000018377A1 (en) | 1998-09-28 | 2000-04-06 | Warner-Lambert Company | Enteric and colonic delivery using hpmc capsules |
| US6485747B1 (en) | 1998-10-30 | 2002-11-26 | Monsanto Company | Coated active tablet(s) |
| PL348193A1 (en) * | 1998-12-11 | 2002-05-06 | Pharmasolutions | Self-emulsifying compositions for drugs poorly soluble in water |
| US6635281B2 (en) * | 1998-12-23 | 2003-10-21 | Alza Corporation | Gastric retaining oral liquid dosage form |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| WO2000057885A1 (en) | 1999-03-31 | 2000-10-05 | Pharmacia & Upjohn Company | Pharmaceutical emulsions for retroviral protease inhibitors |
| WO2000071122A1 (en) | 1999-05-20 | 2000-11-30 | Par Pharmaceutical, Inc. | Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process |
| TWI243672B (en) * | 1999-06-01 | 2005-11-21 | Astrazeneca Ab | New use of compounds as antibacterial agents |
| US6126816A (en) * | 1999-07-14 | 2000-10-03 | Ruiz, Jr.; Reuben F. | Wastewater treatment device |
| US20020102301A1 (en) * | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
| US6787164B2 (en) | 2000-02-23 | 2004-09-07 | Bioselect Innovations, Inc. | Composition and method for treating the effects of diseases and maladies |
| SE0000773D0 (en) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| US20020044962A1 (en) | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
| SE0002476D0 (en) | 2000-06-30 | 2000-06-30 | Astrazeneca Ab | New compounds |
| US6544556B1 (en) | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| US20020045184A1 (en) | 2000-10-02 | 2002-04-18 | Chih-Ming Chen | Packaging system |
| FR2818905A1 (en) * | 2000-12-28 | 2002-07-05 | Cll Pharma | MICELLAR COLLOIDAL PHARMACEUTICAL COMPOSITIONS COMPRISING A LIPOPHILIC ACTIVE INGREDIENT |
| AR036354A1 (en) | 2001-08-31 | 2004-09-01 | Takeda Chemical Industries Ltd | SOLID PREPARATION |
| US7467633B2 (en) * | 2005-03-10 | 2008-12-23 | Huntsman Petrochemical Corporation | Enhanced solubilization using extended chain surfactants |
-
2000
- 2000-03-08 SE SE0000774A patent/SE0000774D0/en unknown
-
2001
- 2001-02-26 AR ARP010100864A patent/AR027554A1/en not_active Application Discontinuation
- 2001-03-06 EP EP01910304A patent/EP1267831B1/en not_active Expired - Lifetime
- 2001-03-06 KR KR1020027011733A patent/KR100771318B1/en not_active IP Right Cessation
- 2001-03-06 BR BRPI0109012-7A patent/BR0109012B1/en not_active IP Right Cessation
- 2001-03-06 AU AU2001237875A patent/AU2001237875B2/en not_active Ceased
- 2001-03-06 HU HU0300539A patent/HU229103B1/en not_active IP Right Cessation
- 2001-03-06 JP JP2001564740A patent/JP4656479B2/en not_active Expired - Fee Related
- 2001-03-06 RU RU2002122745/15A patent/RU2275908C2/en not_active IP Right Cessation
- 2001-03-06 AT AT01910304T patent/ATE311173T1/en active
- 2001-03-06 AU AU3787501A patent/AU3787501A/en active Pending
- 2001-03-06 DK DK01910304T patent/DK1267831T3/en active
- 2001-03-06 CN CNB018062938A patent/CN1283229C/en not_active Expired - Fee Related
- 2001-03-06 EE EEP200200483A patent/EE200200483A/en unknown
- 2001-03-06 SK SK1258-2002A patent/SK285749B6/en not_active IP Right Cessation
- 2001-03-06 CZ CZ20023006A patent/CZ303524B6/en not_active IP Right Cessation
- 2001-03-06 WO PCT/SE2001/000466 patent/WO2001066087A1/en active IP Right Grant
- 2001-03-06 DE DE60115402T patent/DE60115402T2/en not_active Expired - Lifetime
- 2001-03-06 US US10/221,079 patent/US7736666B2/en not_active Expired - Fee Related
- 2001-03-06 MX MXPA02008658A patent/MXPA02008658A/en active IP Right Grant
- 2001-03-06 ES ES01910304T patent/ES2253354T3/en not_active Expired - Lifetime
- 2001-03-06 SI SI200130487T patent/SI1267831T1/en unknown
- 2001-03-06 IL IL15138001A patent/IL151380A0/en not_active IP Right Cessation
- 2001-03-06 CA CA002401857A patent/CA2401857A1/en not_active Abandoned
- 2001-03-07 MY MYPI20011044A patent/MY137749A/en unknown
- 2001-06-03 UA UA2002086882A patent/UA76098C2/en unknown
-
2002
- 2002-09-03 IS IS6538A patent/IS6538A/en unknown
- 2002-09-03 NO NO20024194A patent/NO331921B1/en not_active IP Right Cessation
- 2002-09-04 ZA ZA200207109A patent/ZA200207109B/en unknown
-
2003
- 2003-08-25 HK HK03106084A patent/HK1053795A1/en not_active IP Right Cessation
-
2010
- 2010-04-28 US US12/768,820 patent/US20100266683A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100266683A1 (en) | New self emulsifying drug delivery system | |
| CA2401498C (en) | New self emulsifying drug delivery system | |
| AU2001237875A1 (en) | New self emulsifying drug delivery system | |
| AU2001237876A1 (en) | New self emulsifying drug delivery system | |
| EP1427392B1 (en) | New self emulsifying drug delivery system | |
| PL203549B1 (en) | The pharmaceutical composition in the form of an emulsion pre-concentrate, unit dosage form, and use of the pharmaceutical composition |